Business Wire

REPLY

17.7.2020 09:32:05 CEST | Business Wire | Press release

Share
Reply Recognised as a Representative Vendor in the 2020 Gartner Market Guide for Yard Management

Reply, with its LEA ReplyTM Supply Chain Execution Suite, is proud to be recognised as a Representative Vendor in Gartner’s 2020 Market Guide for Yard Management .

According to Gartner, “recent disruptions such as COVID-19 have highlighted lack of focus in the yard. These disruptions have caused longer dwell times for carriers and other inefficiencies. This is causing a renewed interest in yard solutions .” The report further states, “The need for more automation and digitization caused by the recent disruptions and concerns around social distancing has created more visibility of the gaps that exist in many yard operations,” and “Companies are looking into YMS solutions to help close the supply chain gaps that exist in their own backyards such as long trailer wait times, unproductive personnel numbers, poorly synchronized movement of goods and ineffective dock planning.”

LEA ReplyTM Yard Management supports the execution of end-to-end yard management activities, with a comprehensive range of features like gate flow, dock scheduling, dock management and yard management.

LEA ReplyTM Yard Management (YMS) comprises of a web interface and mobile application. The solution offers maximum visibility and control, expediting inbound and outbound transits, reducing in-yard traffic and providing advanced options for yard stocking.

LEA ReplyTM YMS and LEA ReplyTM Dock Scheduling can be used as standalone applications, in parallel or incorporated with other supply chain execution solutions making up the LEA ReplyTM Suite .

The report further provides, “according to the findings in the Modern Materials Handling Annual Warehouse and Distribution Center Automation Survey: ‘The companies that want to upgrade existing or implement new SCE software in the next two years have their sights set on WMS (56%), WCS (43%), YMS (43%), TMS (41%) and warehouse execution systems (41%).’”

Gartner subscribers can view the full report here .

Gartner, “Market Guide for Yard Management”, Simon Tunstall, Bart De Muynck, 25 June 2020.

GARTNER - DISCLAIMER
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s Research & Advisory organization and should not be construed as statements of fact. Gartner disclaims all warranties, express or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

REPLY
Reply [MTA, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press release

Intranasal pertussis vaccine candidate BPZE1 demonstrates robust nasal mucosal and systemic immune responses with a favorable safety profile in children ages 6 through 17 yearsFirst pediatric clinical trial builds on 5 prior adult BPZE1 clinical studiesDemonstrates safety and immunogenicity of BPZE1 in acellular pertussis vaccine primed individualsNo interference observed when BPZE1 co-administered with diphtheria and tetanus antigens ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The stu

NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising2.10.2026 12:45:00 CEST | Press release

New AI and automation capabilities help retailers close execution gaps and scale merchandising decisions across every store. NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access. "Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time buil

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.10.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and restricted share units covering an aggregate of 58,000 shares. The options have an exercise price per share equal to $12.44. The equity awards to the ten newly hired non-executive employees were granted on October 1, 2026 and consisted of options to purchase an aggregate of 97,100 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 46,200 shares. These options have an exercise price per share equal to $11.95, the closing price of the Company’s American De

Global Health Leaders to Convene at Abu Dhabi Future Health Summit 20262.10.2026 12:24:00 CEST | Press release

Abu Dhabi Future Health Summit will convene leaders across healthcare, science, technology, policy, and investment from 20-22October at ADNEC Centre Abu DhabiUnder the 2026 theme ‘To Sense is to Predict’, the Future Health Summit will examine how greater health insight can enable earlier intervention and better outcomesAstraZeneca CEO Sir Pascal Soriot, Isomorphic Labs President Mr. Max Jaderberg, Amref Health Africa Group CEO Dr. Githinji Gitahi, and Health Ministers from Kosovo, Montenegro, Serbia and Colombia are among more than 130 Forum speakers, with participation expected from 100 countries Global leaders across healthcare, science, technology, policy, and investment will convene at the Abu Dhabi Future Health Summit from 20 to 22 October 2026 to examine how health systems can better anticipate risk and enable earlier intervention as advances in AI, genomics, diagnostics, and health data create new possibilities for understanding health risks earlier. This press release features

Venture Global and ConocoPhillips Announce 20-Year LNG Sales and Purchase Agreement1.10.2026 22:30:00 CEST | Press release

Today, Venture Global, Inc. (NYSE: VG) and ConocoPhillips (NYSE: COP) announced a new, long-term Sales and Purchase Agreement (SPA) for liquefied natural gas (LNG). Under the SPA, ConocoPhillips will buy 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. "Venture Global is proud to welcome ConocoPhillips, one of the world's leading energy companies, as a long-term partner," said Venture Global CEO Mike Sabel. "This agreement reflects continued market confidence in our proven ability to deliver reliable, low-cost U.S. LNG quickly and at scale. We look forward to supporting ConocoPhillips' growing global LNG portfolio for decades to come." About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye